CELG is one of the few mid-cap biotechs I’ve never had from either the long side or the short side. On a cursory inspection, the current valuation seems high, but I don’t follow the company closely enough to have a strong opinion about it.
>…why short rather than trade puts?<
It’s easier to predict the direction in which a stock price will move than to predict both the direction and the timing.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”